Innate Pharma (IPHA) Change in Intangibles (2019 - 2023)

Innate Pharma (IPHA) has reported Change in Intangibles for 5 consecutive years, with -$2.3 million the latest figure, recorded in Q4 2023.

• Quarterly Change in Intangibles fell 240.72% year-over-year to -$2.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$3.4 million (up 73.49% YoY) and the FY2023 annual result came in at -$2.3 million, changed N/A from the prior year.
• Change in Intangibles slipped to -$2.3 million in Q4 2023 per IPHA's latest filing, from -$667979.2 in the prior quarter.
• Over the last five years, Change in Intangibles for IPHA reached as high as -$37552.5 in Q2 2021 and fell as low as -$73.0 million in Q2 2019.
• A 5-year average of -$21.5 million and a median of -$6.4 million in 2023 frame the typical range for Change in Intangibles.
• Annual changes were most pronounced in 2021 — Change in Intangibles soared 99.65% — and 2023, when it sank 240.72%.
• Year by year, Change in Intangibles stood at -$73.0 million in 2019, then surged by 83.82% to -$11.8 million in 2020, then surged by 96.13% to -$456319.7 in 2021, then slumped by 46.38% to -$667979.2 in 2022, then plunged by 240.72% to -$2.3 million in 2023.
• According to Business Quant data, Change in Intangibles over the past three periods registered -$2.3 million, -$667979.2, and -$456319.7 for Q4 2023, Q4 2022, and Q4 2021 respectively.